FANCC Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant FANCC.
|Application ||WB, IF|
|Calculated MW||63429 Da|
|Other Names||Fanconi anemia group C protein, Protein FACC, FANCC, FAC, FACC|
|Target/Specificity||FANCC (NP_000127, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||FANCC Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group C.
Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Pace P, et al. Science, 2010 Jul 9. PMID 20538911.Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Palagyi A, et al. Mol Cancer, 2010 May 28. PMID 20509860.Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Monsees GM, et al. Breast Cancer Res Treat, 2010 May 23. PMID 20496165.Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.
If you have any additional inquiries please email technical services at email@example.com.